Quibim, a leading healthtech company pioneering the use of imaging biomarkers for precision medicine, has secured $50 million in a Series A funding round led by Asabys and Buenavista Equity Partners, with the participation of GoHub Ventures and UI Investissement. Existing investors, including Amadeus Capital Partners, APEX Ventures, Partech, Adara Ventures, Leadwind, and Tony Fadell’s Build Collective, and individual investor Dr. Jonathan Milner, founder of Abcam, also joined the round.
Over the past year, the company has experienced remarkable growth in the number of patients analyzed by its products. Driven by several regulatory approvals and global commercial partnerships patient, analysis surged by 168% quarter-on-quarter.
Quibim is dedicated to the ambitious mission of unlocking a complete, non-invasive understanding of every tissue point in the human body, at any moment in time. To achieve this, the company develops foundational AI models applied to imaging that extract actionable insights from MRI, CT, and PET scans. These insights enable precise characterization of phenotypes and prediction of outcomes in areas such as oncology, immunology, neurology and metabolic disorders.
This is the pathway toward achieving human digital twins; dynamic models that not only reflect and allow health monitoring, but also enhance patient stratification, improve the success rates of drug development programs, and enable treatment testing before application. Today, the company is building digital twins at the organ and lesion level, exemplified by its solutions QP-Brain, QP-Prostate, and QP-Liver.
However, as the volume of whole-body scans and related imaging data continues to grow, in the coming years Quibim models will analyze the entire body. The company’s vision is to catalyze this revolutionary step in healthcare by merging imaging technologies, computing, and artificial intelligence.
$50 Million to Fuel Global Growth
Through the $50M Series A financing, Quibim is establishing a strong presence in the U.S., building on its success in Europe, through strategic collaborations with hospitals and pharmaceutical companies. By implementing its strategic plan and, through its suite of solutions already cleared by the FDA, the company will support healthcare providers and clinical researchers to process an unprecedented amount of data from medical scans. Additionally, Quibim’s AI-powered imaging solutions will empower pharmaceutical companies by enhancing clinical trials and accelerating drug development with precise, actionable insights derived from imaging biomarkers.
“Quibim’s mission is to turn imaging into a catalyst for precision health, and we are deeply grateful to both our new and current investors for their support,” said Dr. Ángel Alberich-Bayarri, CEO and co-founder of Quibim. “Our global expansion into the U.S. is a critical milestone as we work with pharmaceutical leaders and healthcare providers to unlock the power of imaging to revolutionize diagnostics and improve patient outcomes.”
With over 170 installations worldwide, including prestigious institutions like Mass General Brigham and Stanford, and regulatory clearances across the U.S., the European Union, the UK, and other regions, Quibim’s technology bridges the gap between research, clinical practice, and drug development. Last year, Philips announced a global partnership with Quibim to integrate its AI models into MR scanners, while the company also secured strategic alliances with leading biopharma giants such as Merck KGaA and Novartis.
“We are thrilled to announce Quibim as our largest investment to date and our first step into healthtech. Led by Ángel and a strong team, Quibim’s remarkable milestones and groundbreaking technology are redefining medical imaging. We share their vision of creating human digital twins and are proud to support their mission to transform healthcare through AI-driven solutions”, expressed Inés Calabuig, Managing Partner at GoHub Ventures.
Pioneering AI Solutions in Medical Imaging
The company’s product portfolio features cutting-edge solutions designed to enhance medical imaging and diagnostics across various domains.
Their flagship product, QP-Prostate®, is designed to enhance prostate cancer detection through an industry-leading AI-powered lesion detection and is CE, UKCA marked, and 510(k) cleared. QP-Brain® is an AI-based software for the early quantification of neurological diseases, including brain atrophy and lesions, also CE, UKCA marked, and 510(k) cleared. For liver diagnostics, Quibim has developed QP-Liver®, an automated AI tool for MR diagnosis of diffuse liver diseases through accurate quantification of tissue fat and iron levels, with CE and UKCA marking.
Additionally, the company has created QP-Insights®: a platform to manage, store and analyze multi-omics data in clinical trials and real-world data studies. It is being used by global biopharmaceutical companies, academic medical centers, and research consortiums, including the European Cancer Imaging Initiative, as part of Europe’s Beating Cancer Plan. Remarkably, QP-Insights manages the world’s largest imaging datasets, encompassing over 100 million medical images.
